Comparison of immune reactivity and pharmacokinetics of two hepatitis B immune globulins in patients after liver transplantation
Ruth Adler, Rifaat Safadi, Yoseph Caraco, Mina Rowe, Amos Etzioni, Yaffa Ashur, Daniel Shouval – 30 December 2003 – Hepatitis B virus (HBV) immune globulin (HBIg) administration will prevent HBV graft reinfection in HBV patients after orthotopic liver transplantation (OLT). However, the expenditure for such prophylaxis is extremely high ranging between $2,000 to $10,000 per month in various countries for an undefined period and presumably for life. As a consequence, there is a need for introduction of additional and less expensive modes of treatment.